



#21

Patent Application  
Attorney Docket No. PC9824AJTJ

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 21st day of February, 2003.

By \_\_\_\_\_

*Deanna L. Miller*

(Signature of person mailing)

Deanna L. Miller

\_\_\_\_\_  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William John Curatolo, et al.:

APPLICATION NO.: 09/380,885 : Examiner: S. Sharareh

FILING DATE: September 7, 1999 : Group Art Unit: 1615

TITLE: Delayed-Release Dosage Forms of Sertraline : \_\_\_\_\_

Hon. Commissioner for Patents  
Washington, D.C. 20231

*RECEIVED*  
*MAR 04 2003*  
*OFFICE OF PETITIONS*

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). Please charge any additional fees to Deposit Account No. 16-1445.

Respectfully submitted,

*Carmella A. O'Gorman*  
Carmella A. O'Gorman  
Attorney for Applicant(s)  
Reg. No. 33,749

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-1847



FEB 27 2003

Conforms with FORM PTO-FB-A820

## **INFORMATION DISCLOSURE**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.